English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis

Karakizlis, H., Nahrgang, C., Strecker, K., Chen, J., Aly, M., Slanina, H., et al. (2022). Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis. CLINICAL IMMUNOLOGY, 236: 108961. doi:10.1016/j.clim.2022.108961.

Item is

Basic

show hide
Genre: Journal Article

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Karakizlis, Hristos, Author
Nahrgang, Christian, Author
Strecker, Kevin, Author
Chen, Jiangping, Author
Aly, Mostafa, Author
Slanina, Heiko, Author
Schuettler, Christian G., Author
Esso, Isla, Author
Wolter, Martin, Author
Todorova, Darina, Author
Jessen, Soenke, Author
Adamik, Andrea, Author
Ronco, Claudio, Author
Seeger, Werner1, Author              
Weimer, Rolf, Author
Sester, Martina, Author
Birk, Horst-Walter, Author
Husain-Syed, Faeq, Author
Affiliations:
1Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Max Planck Society, ou_2591698              

Content

show
hide
Free keywords: -
 Abstract: Patients receiving maintenance dialysis (MD) are vulnerable to COVID-19-related morbidity and mortality. Currently, data on SARS-CoV-2-specific cellular and humoral immunity post-vaccination in this population are scarce. We conducted a prospective single-center study exploring the specific cellular (interferon-. and interleukin-2 ELISpot assays) and humoral immune responses (dot plot array and chemiluminescent microparticle immunoassay [CMIA]) at 4 weeks and 6 weeks following a single dose or a complete homologous dual dose SARS-CoV-2 vaccine regimen in 60 MD patients (six with a history of COVID-19). Our results show that MD patients exhibit a high seroconversion rate (91.7%) but the anti-spike IgG antibodies (CMIA) tend to wane rapidly after full immunization. Only 51.7% of the patients developed T cell immune response. High anti-spike IgG antibodies may predict a better cellular immunity. While patients with prior COVID-19 showed the best response after one, SARS-CoV-2-naive patients may benefit from a third vaccine injection.

Details

show
hide
Language(s):
 Dates: 2022-02-25
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: ISI: 000788564800014
DOI: 10.1016/j.clim.2022.108961
PMID: 35227871
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: CLINICAL IMMUNOLOGY
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 236 Sequence Number: 108961 Start / End Page: - Identifier: ISSN: 1521-6616